Table 3.

Multivariate Cox proportional hazards regression analysis of RFS, including interaction of signatures with adjuvant chemotherapy

mRNA signaturemRNA–lncRNA signature
Training setValidation setTraining setValidation set
VariableaHR (95% CI)PHR (95% CI)PHR (95% CI)PHR (95% CI)P
Chemotherapy (non-taxane as reference)0.49 (0.15–1.57)0.2281.22 (0.25–5.95)0.8040.69 (0.17–2.74)0.5931.41 (0.27–7.26)0.683
Signature (low-risk as reference)4.46 (1.34–14.91)0.0156.31 (1.20–33.26)0.03010.00 (2.53–39.47)0.00114.04 (1.56–126.71)0.019
Interaction1.82 (0.62–5.37)0.2774.14 (0.93–18.48)0.0635.74 (1.54–21.33)0.0094.46 (1.00–19.88)0.05
  • aAdjusted by Cox proportional hazards models including clinical variables as categorized in Table 2. Here, we present only three items: chemotherapy, signature, and the interaction between them. Other parameters (age, menopausal status, tumor grade, tumor size, positive lymph nodes and radiotherapy) are not shown.